相关实验视频

Updated: Mar 14, 2026

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor
07:16

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor

Published on: September 13, 2018

20.8K

在肺动脉高血压中准Hippo通路:新兴的药理学策略

Dangning Zheng1, Yanzi Guo2

  • 1Engineering Research Centre of Tropical Medicine Innovation and Transformation, Ministry of Education, International Joint Research Centre of Human-machine Intelligent Collaborative for Tumour Precision Diagnosis and Treatment of Hainan Province, School of Pharmacy, Hainan Medical University.

Journal of hypertension
|March 12, 2026
PubMed
概括

河马信号通路通过控制细胞生长和血管重塑来调节肺动脉高血压 (PAH). 准这种途径对治疗PAH有希望,但其复杂的作用需要进一步研究.

关键词:
在 AKT AKT 里面.由AMP激活的蛋白质激酶激活的蛋白质激酶.这就是AMPKK.这就是Arg1的意思.在BACH1的基础上.这就是BMPR2的原因.BTB和CNC的同类性 1在CTGF中,CTGF是CTGF.CYR61 一个年轻人在EMT中,EMT是EMT.最终的MT 结束的MT这是EpoR-β.FOXM1 叉头盒子蛋白质 O3/M1这是FOXO3/FOXO3/FOXO3/FOXO3/FOXO3.这就是HIF-1α.这就是HOXA4A4的意思.河马的路径 河马的路径它们包括IL-1β/IL-6/IL-10.一个ILK1一个ILK1在LATS1/2在LPS中使用LPS.在MAPK/ERK1中.肺动脉附带性纤维细胞的PAAF细胞亚太国家经济体 (PAECs) 是一个PAEC.有机气体/PAFs/PAFs/PAFs/PAFs/PAFs/PAFs/PAFs/PAFs/PAFs.这些PAH是PAH.在PASMC中,PASMCs是指PASMC.这是一个PCNA,PCNA,PCNA.据PDGF的说法,这是一个很好的方法.在PECAM-1/CD31中使用.在PI3K中,PI3K是指PI3K.这种PPARα是氧酶增殖器激活的受体delta/alpha.在PPAR/δ/这是PTPRBB.这是一个RVSP,RVSP.在S1P/S1PR2中.SM22α 没有了这就是SPHK1的原因.在STAT3中,我们可以使用STAT3.塔兹 (TAZ) 是一个名为塔兹 (TAZ) 的城市.在TAZ转录协激活剂蛋白质中.在TGF-β/TGF-β1转化生长因子β/β 1 转化生长因子β/β 1这就是TNF-α.在VCAM1中使用VCAM1.在VEGFR1/2的基础上.在VSMC中,VSMC是VSMC.一个YAP1一个YAP1在YAP1蛋白质中,YAP1是是的相关蛋白1 是的相关蛋白1阿尔法-平滑肌肉的行为蛋白.阿尔金纳-1的使用.骨形态遗传性蛋白质受体2型细胞的增殖细胞的增殖.结合性组织生长因子富含氨酸的血管原生诱导剂 61内皮细胞到介质细胞的过渡.表皮介质介质的过渡.红色素受体β亚单元 红色素受体β亚单位在Homeobox A4中使用.缺氧诱导因子1-αα.这是一种炎症性炎症.整合素连接酶1的作用.互白素-1β/6/1010的使用情况大型瘤抑制酶1/2 1/2脂多糖类糖化物 (Lipopolysaccharide) 是一种脂多糖类糖.mPAPP 这是一个很好的方法.mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR/mTOR is also known as the name of the name of the name of the name of the name of the name of the name of the name of the company that owns the name of the company that owns the companymTORC1是拉巴胺/mTOR复合体1的机械性标.平均肺动脉压力 肺动脉压力微型RNA (miR) 是一种微型RNA.这是一个微型RNA.中原激活蛋白激酶/细胞外信号调节蛋白激酶1酸的3-酸酶是什么?血小板内皮细胞粘附分子-1-1来自血小板的生长因子.增殖细胞核抗原的核抗原.蛋白质激酶B的蛋白质激酶B.蛋白质铁酸酸酶受体B型肺动脉内皮细胞 肺动脉内皮细胞肺动脉高血压 肺动脉高血压肺动脉脉平滑肌肉细胞 细胞肺动脉平滑肌肉细胞肺动脉平滑肌肉细胞肺高血压是一种肺高血压.右心室缩压的右心室缩压信号转换器和转录的激活器 3 3滑动肌肉22αα是指一个平滑的肌肉.斯芬戈氨酸激酶 1 的作用.斯芬戈-1-酸盐/S1P受体 2 2 的作用.具有PDZ结合动机的转录协活性剂.瘤丧亡因子α因子血管细胞粘附分子 1 1血管内皮生长因子受体 1/2 1/2血管改造 血管改造 血管改造血管光滑肌肉细胞细胞α-SMAMA 的使用.

更多相关视频

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.7K
Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

1.0K

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
615
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
579
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
531
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
764
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
682
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
714